{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:59:49Z","timestamp":1777535989680,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,2,29]],"date-time":"2012-02-29T00:00:00Z","timestamp":1330473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00228-012-1228-3","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T08:33:19Z","timestamp":1330417999000},"page":"1147-1156","source":"Crossref","is-referenced-by-count":16,"title":["Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain"],"prefix":"10.1007","volume":"68","author":[{"given":"Kristin","family":"Moksnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein","family":"Kaasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8rnulf","family":"Paulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Henrik","family":"Rosland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olav","family":"Spigset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,29]]},"reference":[{"issue":"5","key":"1228_CR1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1054\/bjoc.2001.1680","volume":"84","author":"GW Hanks","year":"2001","unstructured":"Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JRI, Sawe J, Twycross RG, Ventafridda V (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84(5):587\u2013593","journal-title":"Br J Cancer"},{"issue":"3","key":"1228_CR2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","volume":"108","author":"RA Totah","year":"2008","unstructured":"Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108(3):363\u2013374. doi: 10.1097\/ALN.0b013e3181642938","journal-title":"Anesthesiology"},{"issue":"3","key":"1228_CR3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/ALN.0b013e3181986a9a","volume":"110","author":"ED Kharasch","year":"2009","unstructured":"Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS (2009) Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir\/indinavir. Anesthesiology 110(3):660\u2013672. doi: 10.1097\/ALN.0b013e3181986a9a","journal-title":"Anesthesiology"},{"issue":"2","key":"1228_CR4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0376-8716(02)00320-4","volume":"69","author":"M Shinderman","year":"2003","unstructured":"Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB (2003) Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend 69(2):205\u2013211","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1228_CR5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2125.2010.03653.x","volume":"70","author":"J Gronlund","year":"2010","unstructured":"Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K (2010) Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol 70(1):78\u201387. doi: 10.1111\/j.1365-2125.2010.03653.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1228_CR6","first-page":"1","volume":"25","author":"BL Coffman","year":"1997","unstructured":"Coffman BL, Rios GR, King CD, Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25(1):1\u20134","journal-title":"Drug Metab Dispos"},{"key":"1228_CR7","doi-asserted-by":"crossref","unstructured":"Nicholson AB (2004) Methadone for cancer pain. Cochrane Database Syst Rev (2): CD003971 doi: 10.1002\/14651858.CD003971.pub2 [doi]","DOI":"10.1002\/14651858.CD003971.pub2"},{"issue":"10","key":"1228_CR8","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.1999.17.10.3307","volume":"17","author":"S Mercadante","year":"1999","unstructured":"Mercadante S, Casuccio A, Calderone L (1999) Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 17(10):3307\u20133312","journal-title":"J Clin Oncol"},{"issue":"5","key":"1228_CR9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s00520-003-0440-1","volume":"11","author":"S Mercadante","year":"2003","unstructured":"Mercadante S, Bianchi M, Villari P, Ferrera P, Casuccio A, Fulfaro F, Gebbia V (2003) Opioid plasma concentration during switching from morphine to methadone: Preliminary data. Support Care Cancer 11(5):326\u2013331","journal-title":"Support Care Cancer"},{"issue":"6","key":"1228_CR10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jpainsymman.2008.05.016","volume":"37","author":"MA Benitez-Rosario","year":"2009","unstructured":"Benitez-Rosario MA, Salinas-Martin A, guirre-Jaime A, Perez-Mendez L, Feria M (2009) Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. J Pain Symptom Manage 37(6):1061\u20131068","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"1228_CR11","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1200\/JCO.1998.16.10.3216","volume":"16","author":"C Ripamonti","year":"1998","unstructured":"Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16(10):3216\u20133221","journal-title":"J Clin Oncol"},{"issue":"6","key":"1228_CR12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3","volume":"82","author":"PG Lawlor","year":"1998","unstructured":"Lawlor PG, Turner KS, Hanson J, Bruera ED (1998) Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 82(6):1167\u20131173","journal-title":"Cancer"},{"issue":"4","key":"1228_CR13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T","volume":"78","author":"E Bruera","year":"1996","unstructured":"Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J (1996) Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78(4):852\u2013857. doi: 10.1002\/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T","journal-title":"Cancer"},{"issue":"1","key":"1228_CR14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1191\/0269216306pm1099oa","volume":"20","author":"OM Fredheim","year":"2006","unstructured":"Fredheim OM, Kaasa S, Dale O, Klepstad P, Landro NI, Borchgrevink PC (2006) Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine-month follow-up study. PalliatMed 20(1):35\u201341","journal-title":"PalliatMed"},{"issue":"1","key":"1228_CR15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1008263910494","volume":"9","author":"C Ripamonti","year":"1998","unstructured":"Ripamonti C, De Conno F, Groff L, Belzile M, Pereira J, Hanson J, Bruera E (1998) Equianalgesic dose\/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 9(1):79\u201383","journal-title":"Ann Oncol"},{"issue":"5","key":"1228_CR16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/0269216310384902","volume":"25","author":"O Dale","year":"2011","unstructured":"Dale O, Moksnes K, Kaasa S (2011) European Palliative Care Research Collaborative pain guidelines: Opioid switching to improve analgesia or reduce side effects. A systematic review Palliat Med 25(5):494\u2013503. doi: 10.1177\/0269216310384902","journal-title":"A systematic review. Palliat Med"},{"issue":"6","key":"1228_CR17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejpain.2006.09.006","volume":"11","author":"OM Fredheim","year":"2007","unstructured":"Fredheim OM, Borchgrevink PC, Klepstad P, Kaasa S, Dale O (2007) Long term methadone for chronic pain: a pilot study of pharmacokinetic aspects. Eur J Pain 11(6):599\u2013604","journal-title":"Eur J Pain"},{"issue":"3","key":"1228_CR18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/01.ftd.0000211827.03726.e4","volume":"28","author":"K Auret","year":"2006","unstructured":"Auret K, Roger Goucke C, Ilett KF, Page-Sharp M, Boyd F, Oh TE (2006) Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. Ther Drug Monit 28(3):359\u2013366","journal-title":"Ther Drug Monit"},{"issue":"6266","key":"1228_CR19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/bmj.282.6266.771","volume":"282","author":"J Sawe","year":"1981","unstructured":"Sawe J, Hansen J, Ginman C, Hartvig P, Jakobsson PA, Nilsson MI, Rane A, Anggard E (1981) Patient-controlled dose regimen of methadone for chronic cancer pain. Br Med J (Clin Res Ed) 282(6266):771\u2013773","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1228_CR20","doi-asserted-by":"crossref","unstructured":"Moksnes K, Dale O, Rosland JH, Paulsen O, Klepstad P, Kaasa S (2011) How to switch from morphine or oxycodone to methadone in cancer patients? A randomised clinical phase II trial Eur J Cancer. doi: 10.1016\/j.ejca.2011.06.047","DOI":"10.1016\/j.ejca.2011.06.047"},{"issue":"2","key":"1228_CR21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0885-3924(01)00294-9","volume":"22","author":"J Pereira","year":"2001","unstructured":"Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E (2001) Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. J Pain Symptom Manage 22(2):672\u2013687","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"1228_CR22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.5694\/j.1326-5377.2000.tb139323.x","volume":"173","author":"OT Ayonrinde","year":"2000","unstructured":"Ayonrinde OT, Bridge DT (2000) The rediscovery of methadone for cancer pain management. Med J Aust 173(10):536\u2013540","journal-title":"Med J Aust"},{"issue":"2","key":"1228_CR23","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23(2):129\u2013138","journal-title":"Ann Acad Med Singapore"},{"issue":"5","key":"1228_CR24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0885-3924(02)00526-2","volume":"24","author":"P Klepstad","year":"2002","unstructured":"Klepstad P, Loge JH, Borchgrevink PC, Mendoza TR, Cleeland CS, Kaasa S (2002) The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. JPain SymptomManage 24(5):517\u2013525","journal-title":"JPain SymptomManage"},{"issue":"1","key":"1228_CR25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpainsymman.2007.12.016","volume":"37","author":"O Dale","year":"2009","unstructured":"Dale O, Piribauer M, Kaasa S, Moksnes K, Knobel H, Klepstad P (2009) A double-blind, randomised, crossover comparison between single-dose and double-dose immediate-release oral morphine at bedtime in cancer patients. J Pain Symptom Manage 37(1):68\u201376. doi: 10.1016\/j.jpainsymman.2007.12.016","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"1228_CR26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jps.2600810324","volume":"81","author":"VP Shah","year":"1992","unstructured":"Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S (1992) Analytical Methods Validation - Bioavailability, Bioequivalence, and Pharmacokinetic Studies. J Pharm Sci 81(3):309\u2013312","journal-title":"J Pharm Sci"},{"issue":"2","key":"1228_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0731-7085(94)00106-C","volume":"13","author":"D Dadgar","year":"1995","unstructured":"Dadgar D, Burnett PE, Choc MG, Gallicano K, Hooper JW (1995) Application issues in bioanalytical method validation, sample analysis and data reporting. J Pharm Biomed Anal 13(2):89\u201397","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"1228_CR28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jchromb.2006.10.039","volume":"848","author":"SR Edwards","year":"2007","unstructured":"Edwards SR, Smith MT (2007) Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 848(2):264\u2013270. doi: 10.1016\/j.jchromb.2006.10.039","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"7","key":"1228_CR29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/00003246-199307000-00012","volume":"21","author":"R Katz","year":"1993","unstructured":"Katz R, Kelly HW (1993) Pharmacokinetics of continuous infusions of fentanyl in critically ill children. Crit Care Med 21(7):995\u20131000","journal-title":"Crit Care Med"},{"issue":"5","key":"1228_CR30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00228-010-0948-5","volume":"67","author":"TN Andreassen","year":"2011","unstructured":"Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundstrom S, Kaasa S, Dale O (2011) Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol 67(5):493\u2013506. doi: 10.1007\/s00228-010-0948-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1228_CR31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archpsyc.55.1.89","volume":"55","author":"CB Eap","year":"1998","unstructured":"Eap CB, Bertschy G, Baumann P, Finkbeiner T, Gastpar M, Scherbaum N (1998) High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry 55(1):89\u201390","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1228_CR32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pharmthera.2009.06.010","volume":"124","author":"J Lotsch","year":"2009","unstructured":"Lotsch J, Geisslinger G, Tegeder I (2009) Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 124(2):168\u2013184. doi: 10.1016\/j.pharmthera.2009.06.010","journal-title":"Pharmacol Ther"},{"issue":"2","key":"1228_CR33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1191\/0269216303pm658oa","volume":"17","author":"C Quigley","year":"2003","unstructured":"Quigley C, Joel S, Patel N, Baksh A, Slevin M (2003) Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med 17(2):185\u2013190","journal-title":"Palliat Med"},{"issue":"2","key":"1228_CR34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0304-3959(94)00268-J","volume":"62","author":"T Wolff","year":"1995","unstructured":"Wolff T, Samuelsson H, Hedner T (1995) Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 62(2):147\u2013154","journal-title":"Pain"},{"issue":"8","key":"1228_CR35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1191\/0269216303pm835oa","volume":"17","author":"P Klepstad","year":"2003","unstructured":"Klepstad P, Borchgrevink PC, Dale O, Zahlsen K, Aamo T, Fayers P, Fougner B, Kaasa S (2003) Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med 17(8):679\u2013687","journal-title":"Palliat Med"},{"issue":"2","key":"1228_CR36","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/0024-3205(94)00426-S","volume":"56","author":"K Kristensen","year":"1995","unstructured":"Kristensen K, Christensen CB, Christrup LL (1995) The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 56(2):PL45\u2013PL50","journal-title":"Life Sci"},{"issue":"5","key":"1228_CR37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0885-3924(95)00021-P","volume":"10","author":"G Hunt","year":"1995","unstructured":"Hunt G, Bruera E (1995) Respiratory depression in a patient receiving oral methadone for cancer pain. JPain SymptomManage 10(5):401\u2013404","journal-title":"JPain SymptomManage"},{"issue":"3","key":"1228_CR38","first-page":"457","volume":"63","author":"DS Ettinger","year":"1979","unstructured":"Ettinger DS, Vitale PJ, Trump DL (1979) Important clinical pharmacologic considerations in the use of methadone in cancer patients. Cancer Treat Rep 63(3):457\u2013459","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"1228_CR39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/jpnu.2003.16","volume":"19","author":"L Bond Sutton","year":"2003","unstructured":"Bond Sutton L, Erlen JA, Glad JM, Siminoff LA (2003) Recruiting vulnerable populations for research: revisiting the ethical issues. J Prof Nurs 19(2):106\u2013112. doi: 10.1053\/jpnu.2003.16","journal-title":"J Prof Nurs"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1228-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-012-1228-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1228-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T17:30:25Z","timestamp":1640971825000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-012-1228-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,29]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1007\/s00228-012-1228-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,29]]}}}